Screener
UroGen Pharma URGN Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Restricted deposit | 178 | 177 |
| Finance lease right-of-use assets | 4,818 | 5,376 |
| Operating lease right-of-use assets | 2,810 | 3,080 |
| Other non-current assets | 8,761 | 5,161 |
| Total assets | $252,590 | $200,455 |
| Liabilities and Shareholders' Deficit | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $39,945 | $27,717 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's deferred tax assets and other non-current assets?
- UroGen Pharma (URGN) reported deferred tax assets and other non-current assets of $8.76M in Q2 2026.
- How has UroGen Pharma's deferred tax assets and other non-current assets changed year-over-year?
- UroGen Pharma's deferred tax assets and other non-current assets increased by 993.8% year-over-year, from $801K to $8.76M.
- What is the long-term trend for UroGen Pharma's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), UroGen Pharma's deferred tax assets and other non-current assets has grown at a 139.1% compound annual growth rate (CAGR), from $66K to $5.16M.
- What does deferred tax assets and other non-current assets mean?
- Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.
Ask your AI about UroGen Pharma's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude